Arenavirus

HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
금요일, 3월 22, 2024
SIV, Clinical trial, Hepatitis, Head, CPI, Serum, Hepatitis B, Partnership, HIV, Oncology, Gilead Sciences, Patient, Lung, Journal, Viral load, Pembrolizumab, HBV, Trial of the century, IND, Infection, Hepatocyte, Arenavirus, Antibody, Vaccination, Intellectual property, FDA, Liver, Animal, Pharmaceutical industry

“It was a defining year for HOOKIPA as we witnessed the powerful potential of our novel arenaviral immunotherapies in action.

Key Points: 
  • “It was a defining year for HOOKIPA as we witnessed the powerful potential of our novel arenaviral immunotherapies in action.
  • Data was initially presented in May 2023 and additional patient data was provided in October at the European Society for Medical Oncology Congress 2023.
  • HOOKIPA expects to initiate a Phase 1 clinical study of HB-500 in people with HIV in the second quarter of 2024.
  • In June 2023, the Company completed a $50.0 million public offering of common stock and non-voting convertible preferred stock.

HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference

Retrieved on: 
수요일, 3월 6, 2024
Conference, Arenavirus

NEW YORK and VIENNA, Austria, March 06, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA’s Chief Financial Officer, Reinhard Kandera, will present at the Leerink Partners Global Biopharma Conference on March 13, 2024.

Key Points: 
  • NEW YORK and VIENNA, Austria, March 06, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA’s Chief Financial Officer, Reinhard Kandera, will present at the Leerink Partners Global Biopharma Conference on March 13, 2024.
  • Webcast details are available below.
  • Leerink Partners Global Biopharma Conference 2024, Miami, Florida

HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs

Retrieved on: 
월요일, 1월 29, 2024
Patient, Neck, HNSCC, Arenavirus, Head, IND, HIV, Investigational New Drug, Workforce, Hepatitis B, Pembrolizumab, Pharmaceutical industry

The totality of the HB-200 data presents a clear opportunity for HOOKIPA to advance this program in a randomized trial starting in mid-2024.

Key Points: 
  • The totality of the HB-200 data presents a clear opportunity for HOOKIPA to advance this program in a randomized trial starting in mid-2024.
  • “HOOKIPA has a tremendous opportunity to transform treatment of multiple disease areas using an entirely new class of medicines,” said Joern Aldag, Chief Executive Officer at HOOKIPA.
  • HOOKIPA will reduce its workforce by approximately 30 percent and rebalance its cost structure in alignment with the new prioritization of the Company’s programs.
  • The strategic priorities for HOOKIPA are to advance its clinical programs including HB-200 and its two Gilead-partnered infectious disease programs.

HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization

Retrieved on: 
화요일, 1월 16, 2024
Bristol Myers Squibb, Partnership, Standard of care, Heidelberg University, Arenavirus, Head, MorphoSys, Drug development, Doctor of Philosophy, Master of Science, Max Planck Society, Management

Dr. Winderlich has rich experience leading multiple candidates through the drug development process to product approval in the United States and in Europe.

Key Points: 
  • Dr. Winderlich has rich experience leading multiple candidates through the drug development process to product approval in the United States and in Europe.
  • “We are pleased to bring our search for a capable clinical development leader to such a swift, successful resolution and welcome Mark to the team,” said Joern Aldag, Chief Executive Officer at HOOKIPA.
  • “Mark is a tremendous talent with rich experience across the drug development lifecycle.
  • Prior to Evotec, Dr. Winderlich spent more than 12 years in drug development at MorphoSys AG across various roles of increasing responsibility.

HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences

Retrieved on: 
목요일, 12월 21, 2023
Partnership, Food, Antigen, Hoʻokipa, Sale, Arenavirus, The Mark of Gideon, Common stock, Investigational New Drug, Equity, HIV, LCMV, Prospectus, Gilead Sciences, Security (finance), Pharmaceutical industry

In addition, HOOKIPA has the right, subject to certain terms and conditions, to sell an additional approximately $8.75 million of common stock to Gilead as pro-rata participation in potential future equity raises.

Key Points: 
  • In addition, HOOKIPA has the right, subject to certain terms and conditions, to sell an additional approximately $8.75 million of common stock to Gilead as pro-rata participation in potential future equity raises.
  • The agreement with Gilead replaces the stock purchase agreement that Hookipa entered into with Gilead in 2022.
  • Following the completion of the stock purchase, Gilead’s ownership in HOOKIPA increased to 18,759,465 shares, or approximately 19.4% of HOOKIPA’s outstanding shares of Common Stock.
  • HB-500 is one of two separate development programs in HOOKIPA’s collaboration and license agreement with Gilead.

HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus

Retrieved on: 
월요일, 11월 20, 2023
SIV, Food, Antigen, IND, Antibody, Arenavirus, FDA, The Mark of Gideon, Simian immunodeficiency virus, Vaccination, NPJ, Animal, HIV, Vaccine, LCMV, Gilead Sciences, Viral load

HOOKIPA is responsible for advancing the HIV program through the completion of a Phase 1b clinical trial.

Key Points: 
  • HOOKIPA is responsible for advancing the HIV program through the completion of a Phase 1b clinical trial.
  • The analyses published were conducted with a simian immunodeficiency virus (SIV) model, commonly used in a preclinical setting as a surrogate to HIV.
  • One vector is based on lymphocytic choriomeningitis virus (LCMV) as its arenaviral backbone; another vector is based on Pichinde virus (PICV).
  • HB-500 is one of two separate development programs in HOOKIPA’s collaboration and license agreement with Gilead.

HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Retrieved on: 
목요일, 11월 9, 2023
Hepatocyte, Prostate-specific antigen, Research, Trial of the century, IND, PSA, Infection, Hepatitis, Pembrolizumab, Head, HIV, Liver, KRAS, Arenavirus, Prostate cancer, Gilead Sciences, Journal, CPI, Development, Gilead, Lung, PAP, Oncology, Serum, Safety, European Society of Gynaecological Oncology, Cancer, Patient, Administration, HBV, The Journal of Infectious Diseases, Investigational New Drug, Pharmaceutical industry, Clothing, Vaccine, Reinsurance

With these encouraging data, we are busy finalizing plans for the randomized trial expected to begin next year,” said Joern Aldag, Chief Executive Officer at HOOKIPA Pharma.

Key Points: 
  • With these encouraging data, we are busy finalizing plans for the randomized trial expected to begin next year,” said Joern Aldag, Chief Executive Officer at HOOKIPA Pharma.
  • Enrollment continued in the ongoing Phase 1/2 study ( NCT05553639 ) of HB-300 for the treatment of advanced prostate cancer.
  • HB-300 is an arenaviral immunotherapy that targets two well-defined self-antigens of prostate cancer, prostatic acid phosphatase (PAP) and prostate-specific antigen (PSA).
  • The decrease was primarily attributable to cash used in operating activities, partly offset by funds resulting from the follow-on financing in June 2023.

HOOKIPA Pharma Presents Positive Biomarker and Translational Data on HB-200 Monotherapy at Society for Immunotherapy of Cancer 2023

Retrieved on: 
금요일, 11월 3, 2023
Neoplasm, Society for Immunotherapy of Cancer, HIV disease progression rates, Arenavirus, SITC, Immunotherapy, Annual general meeting, Tumor microenvironment, Safety, Patient, Vaccine, Pharmaceutical industry, Medical imaging

The data were presented in a poster presentation (abstract #679) at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting.

Key Points: 
  • The data were presented in a poster presentation (abstract #679) at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting.
  • The goal of the trial was to determine the recommended dose for further evaluation in a Phase 2 study.
  • Phase 1 data also consistently demonstrate that HB-200 was generally well tolerated among 93 patients treated across all dose-level cohorts.
  • This favorable tolerability profile highlights the potential of HB-200—and arenaviral immunotherapies in general—to be safely combined with other immunotherapies.

HOOKIPA Pharma to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 9, 2023

Retrieved on: 
목요일, 11월 2, 2023
Arenavirus, Mobile phone, Audit, Cryptocurrency

NEW YORK and VIENNA, Austria, Nov. 02, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release its third quarter 2023 financial results and business highlights on November 9, 2023.

Key Points: 
  • NEW YORK and VIENNA, Austria, Nov. 02, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release its third quarter 2023 financial results and business highlights on November 9, 2023.
  • The company will not be conducting a conference call in conjunction with this financial release.

HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023

Retrieved on: 
일요일, 10월 22, 2023
Neoplasm, The Mark of Gideon, E6, ESMO, Progression-free survival, DCR, Pembrolizumab, LCMV, Congress, Arenavirus, E7, CPI, Memorial Sloan Kettering Cancer Center, HPV16, COVID, Immune system, Oncology, ORR, ELISPOT, RECIST, DCO, Safety, Patient, Pharmaceutical industry, Vaccine

All evaluable patients were alive at the data cutoff (DCO), and the median follow-up time at DCO was 8.3 months.

Key Points: 
  • All evaluable patients were alive at the data cutoff (DCO), and the median follow-up time at DCO was 8.3 months.
  • Importantly, results showed significant activation of antigen-specific CD8+ T cells, the body’s primary driver of tumor killing activity.
  • Out of 17 patients with available peripheral blood mononuclear cells (PMBC) samples, all patients showed an increase of tumor antigen-specific circulating HPV16+ CD8+ T cells.
  • These data represent a doubling of the 19 percent ORR reported for pembrolizumab alone1 and are consistent with previously reported HB-200 data.